Patients carrying the *3 allele in combination with another no function or a normal function allele may have increased exposure to dabigatran as compared to patients with two normal function alleles. Other genetic and clinical factors may also affect a patient's exposure to dabigatran. This annotation only covers the pharmacokinetic relationship between CYP3A5 and dabigatran and does not include evidence about clinical outcomes.